Indications
Iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating mutations of epidermal-growth-factor-receptor tyrosine kinase.
Composition
- Active substance
- gefitinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Iressa
- Active substance
- gefitinib
- ATC code
- L01XE02
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- Marketing authorisation holder
- AstraZeneca AB
- Status
- Authorised